In the second session of Nanopharm’s fireside series in partnership with FLUIDDA, industry experts Drs. Will Ganley and Eleanor Canipa from Nanopharm and Dr. Jan De Backer from Fluidda provide their thoughts on what the updated PSGs and alternative bioequivalence tell us about the FDA’s position on inhaled generics.
Articles
From ‘Quality Police’ to Lighthouse Leadership: Transforming QA in Pharma | Nanopharm
Discover how Nanopharm is redefining Quality Assurance as a strategic enabler in drug development. Learn how risk-based QA, innovation, and digital tools are improving outcomes for inhaled and nasal therapies.
April 8, 2026
No Comments
